EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL • US30161Q1040

43.63 USD
-0.53 (-1.2%)
At close: Feb 20, 2026
44 USD
+0.37 (+0.85%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

8

Taking everything into account, EXEL scores 8 out of 10 in our fundamental rating. EXEL was compared to 520 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on EXEL. This makes EXEL very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year EXEL was profitable.
  • EXEL had a positive operating cash flow in the past year.
  • In the past 5 years EXEL has always been profitable.
  • EXEL had a positive operating cash flow in each of the past 5 years.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • EXEL has a better Return On Assets (27.51%) than 97.70% of its industry peers.
  • Looking at the Return On Equity, with a value of 36.21%, EXEL belongs to the top of the industry, outperforming 97.89% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 29.21%, EXEL belongs to the top of the industry, outperforming 98.85% of the companies in the same industry.
  • EXEL had an Average Return On Invested Capital over the past 3 years of 18.74%. This is in line with the industry average of 18.69%.
  • The last Return On Invested Capital (29.21%) for EXEL is above the 3 year average (18.74%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 27.51%
ROE 36.21%
ROIC 29.21%
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • The Profit Margin of EXEL (33.73%) is better than 96.55% of its industry peers.
  • In the last couple of years the Profit Margin of EXEL has grown nicely.
  • EXEL's Operating Margin of 38.48% is amongst the best of the industry. EXEL outperforms 97.89% of its industry peers.
  • EXEL's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 96.39%, EXEL belongs to the best of the industry, outperforming 96.74% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 38.48%
PM (TTM) 33.73%
GM 96.39%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, EXEL has less shares outstanding
  • Compared to 5 years ago, EXEL has less shares outstanding
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • EXEL has an Altman-Z score of 12.53. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.53, EXEL belongs to the top of the industry, outperforming 84.45% of the companies in the same industry.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.53
ROIC/WACC3.35
WACC8.72%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • EXEL has a Current Ratio of 3.56. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
  • EXEL has a Current ratio (3.56) which is in line with its industry peers.
  • A Quick Ratio of 3.50 indicates that EXEL has no problem at all paying its short term obligations.
  • EXEL has a Quick ratio (3.50) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.5
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.73% over the past year.
  • Measured over the past years, EXEL shows a very strong growth in Earnings Per Share. The EPS has been growing by 51.25% on average per year.
  • EXEL shows a small growth in Revenue. In the last year, the Revenue has grown by 6.98%.
  • The Revenue has been growing by 18.63% on average over the past years. This is quite good.
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%

3.2 Future

  • EXEL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.
  • The Revenue is expected to grow by 7.52% on average over the next years.
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • EXEL is valuated correctly with a Price/Earnings ratio of 15.75.
  • Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.78% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (26.99), we can say EXEL is valued slightly cheaper.
  • The Price/Forward Earnings ratio is 13.42, which indicates a correct valuation of EXEL.
  • EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.74% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. EXEL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 15.75
Fwd PE 13.42
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 97.50% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.36
EV/EBITDA 10.92
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
  • EXEL's earnings are expected to grow with 19.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.91
PEG (5Y)0.31
EPS Next 2Y21.2%
EPS Next 3Y19.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXELIXIS INC

NASDAQ:EXEL (2/20/2026, 8:00:01 PM)

After market: 44 +0.37 (+0.85%)

43.63

-0.53 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)05-11
Inst Owners97.46%
Inst Owner Change1%
Ins Owners2.18%
Ins Owner Change-2.81%
Market Cap11.70B
Revenue(TTM)2.32B
Net Income(TTM)782.57M
Analysts74.81
Price Target46.75 (7.15%)
Short Float %10.66%
Short Ratio10.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.16%
Min EPS beat(2)7.04%
Max EPS beat(2)9.27%
EPS beat(4)4
Avg EPS beat(4)19.83%
Min EPS beat(4)7.04%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)29.32%
EPS beat(12)9
Avg EPS beat(12)15.98%
EPS beat(16)13
Avg EPS beat(16)18.75%
Revenue beat(2)0
Avg Revenue beat(2)-1.79%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)0.68%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.27%
Revenue beat(12)4
Avg Revenue beat(12)2.32%
Revenue beat(16)6
Avg Revenue beat(16)1.65%
PT rev (1m)1.1%
PT rev (3m)1.85%
EPS NQ rev (1m)-5.13%
EPS NQ rev (3m)-4.6%
EPS NY rev (1m)0.22%
EPS NY rev (3m)11.98%
Revenue NQ rev (1m)-0.9%
Revenue NQ rev (3m)-3.3%
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-0.98%
Valuation
Industry RankSector Rank
PE 15.75
Fwd PE 13.42
P/S 5.04
P/FCF 13.36
P/OCF 13.23
P/B 5.41
P/tB 5.58
EV/EBITDA 10.92
EPS(TTM)2.77
EY6.35%
EPS(NY)3.25
Fwd EY7.45%
FCF(TTM)3.27
FCFY7.49%
OCF(TTM)3.3
OCFY7.56%
SpS8.65
BVpS8.06
TBVpS7.82
PEG (NY)0.91
PEG (5Y)0.31
Graham Number22.41
Profitability
Industry RankSector Rank
ROA 27.51%
ROE 36.21%
ROCE 36.6%
ROIC 29.21%
ROICexc 51.64%
ROICexgc 54.14%
OM 38.48%
PM (TTM) 33.73%
GM 96.39%
FCFM 37.75%
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
ROICexc(3y)32.95%
ROICexc(5y)27.65%
ROICexgc(3y)34.51%
ROICexgc(5y)29.16%
ROCE(3y)23.48%
ROCE(5y)18.07%
ROICexgc growth 3Y66.65%
ROICexgc growth 5Y32.48%
ROICexc growth 3Y66.54%
ROICexc growth 5Y33.67%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 29.01%
Cap/Sales 0.36%
Interest Coverage 250
Cash Conversion 95.93%
Profit Quality 111.92%
Current Ratio 3.56
Quick Ratio 3.5
Altman-Z 12.53
F-Score7
WACC8.72%
ROIC/WACC3.35
Cap/Depr(3y)95.03%
Cap/Depr(5y)177.94%
Cap/Sales(3y)1.3%
Cap/Sales(5y)2.02%
Profit Quality(3y)127.23%
Profit Quality(5y)142.21%
High Growth Momentum
Growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
EBIT growth 1Y29.39%
EBIT growth 3Y64.24%
EBIT growth 5Y51.98%
EBIT Next Year12.21%
EBIT Next 3Y-11.05%
EBIT Next 5Y-5.67%
FCF growth 1Y30.42%
FCF growth 3Y37.77%
FCF growth 5Y37.42%
OCF growth 1Y26.33%
OCF growth 3Y34.6%
OCF growth 5Y33.44%

EXELIXIS INC / EXEL FAQ

What is the fundamental rating for EXEL stock?

ChartMill assigns a fundamental rating of 8 / 10 to EXEL.


Can you provide the valuation status for EXELIXIS INC?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.


Can you provide the profitability details for EXELIXIS INC?

EXELIXIS INC (EXEL) has a profitability rating of 9 / 10.


Can you provide the financial health for EXEL stock?

The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.


What is the expected EPS growth for EXELIXIS INC (EXEL) stock?

The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 17.33% in the next year.